In patients with advanced-stage cervical cancer undergoing CCRT, Chen et al. [10] reported that pretreatment CEA > 10 ng/mL portends worse cancer-specific survival and disease-free survival. This evidence concerns the gene CEACAM5 and cervical cancer.